Submission of Audited Financial Results along with Auditors Report for the Quarter and Year Ended March 31st 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venmax Drugs reported total revenue of Rs. 186.05 lakhs for FY25, up sharply from Rs. 19.86 lakhs in FY24, but most of the growth came from 'other income' (Rs. 105.32 lakhs) rather than core operations. Revenue from operations rose from zero to Rs. 80.73 lakhs. Despite the topline jump, the company slipped into a net loss of Rs. 1.05 lakhs for the year (vs profit of Rs. 6.45 lakhs in FY24), as total expenses surged to Rs. 187.46 lakhs from Rs. 11.17 lakhs, driven by stock-in-trade purchases and other expenses. The company allotted 1,00,25,000 convertible equity share warrants on a preferential basis, receiving 25% upfront, which pushed cash to Rs. 248.24 lakhs and turned equity positive at Rs. 441.19 lakhs. Operating cash flow was deeply negative at Rs. -229.02 lakhs, and accumulated losses in Other Equity stood at Rs. -589.95 lakhs. The statutory auditor (PPKG & Co.) issued an unmodified opinion.
Mixed signals for shareholders: revenue from operations showed real growth, but the company reported a small net loss, sharply negative operating cash flow, and remains heavily loss-making on an accumulated basis. The fresh warrant money provides short-term liquidity, but full conversion will lead to significant equity dilution.